Med-psych drug-drug interactions update - Antihistamines

被引:19
作者
Armstrong, SC
Cozza, KL
机构
[1] Tual Forest Grove Hosp, Ctr Geriatr Psychiat, Forest Grove, OR 97116 USA
[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[3] Walter Reed Army Med Ctr, Dept Med, Infect Dis Serv, Washington, DC 20307 USA
[4] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA
关键词
D O I
10.1176/appi.psy.44.5.430
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Antihistamines and their drug-drug interactions are reviewed in depth. The metabolism of "classic " or sedating antihistamines is coming to light through in vivo and in vitro studies. The polymorphic CYP 2D6 metabolic enzyme appears to be potently inhibited by many of these over-the-counter medications. The history of the discontinued "second-generation " antihistamines terfenadine and astemizole is reviewed to remind the reader why the understanding of the cytochrome P450 system became increasingly important when the cardiotoxicity of these drugs became apparent. The "third-generation " nonsedating antihistamines are also listed and compared. They have been exhaustively scrutinized for drug-drug interactions and cardiotoxicity, and they appear to have no serious drug-drug interactions at recommended doses.
引用
收藏
页码:430 / 434
页数:5
相关论文
共 31 条
[1]   Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation [J].
Abernethy, DR ;
Barbey, JT ;
Franc, J ;
Brown, KS ;
Feirrera, I ;
Ford, N ;
Salazar, DE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :96-103
[2]  
[Anonymous], 2002, Med Lett Drugs Ther, V44, P27
[3]   Consultation-liaison psychiatry drug-drug interactions update [J].
Armstrong, SC ;
Cozza, KL .
PSYCHOSOMATICS, 2001, 42 (03) :269-272
[4]  
Armstrong Scott C, 2002, Psychosomatics, V43, P169, DOI 10.1176/appi.psy.43.2.169
[5]   Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers [J].
Baltes, E ;
Coupez, R ;
Giezek, H ;
Voss, G ;
Meyerhoff, C ;
Benedetti, MS .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2001, 15 (04) :269-277
[6]   Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole [J].
Banfield, C ;
Herron, J ;
Keung, A ;
Padhi, D ;
Affrime, M .
CLINICAL PHARMACOKINETICS, 2002, 41 (Suppl 1) :37-44
[7]   Lack of clinically relevant interaction between desloratadine and erythromycin [J].
Banfield, C ;
Hunt, T ;
Reyderman, L ;
Statkevich, P ;
Padhi, D ;
Affrime, M .
CLINICAL PHARMACOKINETICS, 2002, 41 (Suppl 1) :29-35
[8]   Loratadine/nefazodone interaction [J].
Barbey, JT .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (05) :403-403
[9]   P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists [J].
Chen, CP ;
Hanson, E ;
Watson, JW ;
Lee, JS .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (03) :312-318
[10]   Evaluation of the safety of fexofenadine from experience gained in general practice use in England in 1997 [J].
Craig-McFeely, PM ;
Acharya, NV ;
Shakir, SAW .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (04) :313-320